Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1272 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-07-31

Study Completion Date

2025-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. To determine if BCG immunisation at birth, compared to no BCG immunisation, leads to a reduction in measures of allergy and infection in the first 12 months of life.
2. To evaluate the immunological mechanisms underlying the non-specific effects of BCG by comparing markers of immunity between the BCG and non-BCG groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study

NCT02444611

Innate Immune Response

COMPLETED NA

Bacille Calmette-Guérin (BCG) Vaccine and Atopy

NCT01420705

Asthma Eczema Food Hypersensitivity

COMPLETED

Measles and BCG Vaccines for Mother and Child

NCT04899765

Vaccine Preventable Disease Measles Mother-Infant Interaction +1 more

RECRUITING PHASE4

BCG Vaccination Delivered Intradermally, Orally and by Combined Routes

NCT00396370

Tuberculosis

COMPLETED PHASE1

Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children.

NCT01694108

Prospective Single-blind Clinical +2 more

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There has been a dramatic rise in allergic diseases worldwide since the 1980s. Asthma rates increased first, followed by eczema, allergic rhinitis and, more recently, food allergy - especially in infants and young children. In Australia, the prevalence of allergic disease is particularly high: up to 30% of children are affected, and eczema and asthma are among the most common chronic diseases of childhood.

Preventing allergic disease by an immunomodulatory intervention early in life would be a major advance with significant implications for individual health and public health resources. Bacillus Calmette-Guérin (BCG) immunisation is a potential intervention with an established safety profile. This vaccine has powerful non-specific effects on the cellular immune response that potentially prime host immunity away from an allergic pathway. Observational data and one small randomised controlled trial (RCT) suggest that BCG immunisation at birth leads to a substantial reduction in allergic disease - however, there is an absence of level 1 evidence.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergy Eczema Respiratory Tract Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No BCG

Group Type NO_INTERVENTION

No interventions assigned to this group

BCG

Mycobacterium bovis BCG (Bacille Calmette Guérin) vaccine, Danish Strain 1331

Group Type EXPERIMENTAL

BCG

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BCG

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BCG vaccine - Denmark strain BCG Denmark Statens Serum Institute BCG vaccine Mycobacterium bovis BCG (Bacille Calmette Guérin), Danish Strain 1331

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Less than 10 days old;
* English speaking mother;
* An informed consent form must be signed and dated by their parent(s) or legally acceptable representative after the nature of the study has been explained and prior to any study assessments/procedures;
* The infant's mother has screened negative for HIV during this pregnancy;
* Born no earlier than eight weeks before estimated date of delivery;
* Birth weight \>1500g.
* The legal guardian expects to be able to complete four online/phone questionnaires over the infant's first 12 months of life and for the infant to be available for skin prick testing at RCH between 12-16 months of age.

Exclusion Criteria

* Any indication for BCG immunisation in the first 12 months of life including:

* likely travel to a high tuberculosis (TB) incidence country in the first year of life.
* Aboriginal and Torres Strait Islander babies living in parts of Australia where the incidence of TB is higher
* newborn babies, if either parent has leprosy or a family history of leprosy
* newborn in contact with a patient with TB.
* Known or suspected HIV infection
* Treatment with corticosteroids or other immunosuppressive therapy, including monoclonal antibodies against tumour necrosis factor-alpha (TNF-alpha) (e.g. infliximab, etanercept, adalimumab).
* Born to a mother treated with bDMARDS (e.g. TNF-alpha blocking monoclonal antibodies) in the 3rd trimester;
* Congenital cellular immunodeficiencies including specific deficiencies of the interferon gamma pathway;
* Malignancies involving bone marrow or lymphoid systems;
* Serious underlying illness including severe malnutrition;
* Medically unstable;
* Generalised septic skin disease and skin conditions such as eczema, dermatitis and psoriasis;
* Significant febrile illness;
* Mother immunosuppressed;
* Family history of immunodeficiency;
* Consanguineous parents;
* Multiple births more than twins.

Maximum Eligible Age

10 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes